Cargando…

Development and Validation of a Nomogram Prognostic Model for Resected Limited-Stage Small Cell Lung Cancer Patients

BACKGROUND: In this study, we developed and validated nomograms for predicting the survival in surgically resected limited-stage small cell lung cancer (SCLC) patients. METHODS: The SCLC patients extracted from the Surveillance, Epidemiology, and End Results database between 2000 and 2014 were revie...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Qingpeng, Li, Jiagen, Tan, Fengwei, Sun, Nan, Mao, Yousheng, Gao, Yushun, Xue, Qi, Gao, Shugeng, Zhao, Jun, He, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349336/
https://www.ncbi.nlm.nih.gov/pubmed/33655361
http://dx.doi.org/10.1245/s10434-020-09552-w
_version_ 1783735547629404160
author Zeng, Qingpeng
Li, Jiagen
Tan, Fengwei
Sun, Nan
Mao, Yousheng
Gao, Yushun
Xue, Qi
Gao, Shugeng
Zhao, Jun
He, Jie
author_facet Zeng, Qingpeng
Li, Jiagen
Tan, Fengwei
Sun, Nan
Mao, Yousheng
Gao, Yushun
Xue, Qi
Gao, Shugeng
Zhao, Jun
He, Jie
author_sort Zeng, Qingpeng
collection PubMed
description BACKGROUND: In this study, we developed and validated nomograms for predicting the survival in surgically resected limited-stage small cell lung cancer (SCLC) patients. METHODS: The SCLC patients extracted from the Surveillance, Epidemiology, and End Results database between 2000 and 2014 were reviewed. Significant prognostic factors were identified and integrated to develop the nomogram using multivariable Cox regression. The model was then validated internally by bootstrap resampling, and externally using an independent SCLC cohort diagnosed between 2000 and 2015 at our institution. The prognostic performance was measured by the concordance index (C-index) and calibration curve. RESULTS: A total of 1006 resected limited-stage SCLC patients were included in the training cohort. Overall, 444 cases from our institution constituted the validation cohort. Seven prognostic factors were identified and entered into the nomogram construction. The C-indexes of this model in the training cohort were 0.723, 0.722, and 0.746 for predicting 1-, 3-, and 5-year overall survival (OS), respectively, and 0.816, 0.710, and 0.693, respectively, in the validation cohort. The calibration curve showed optimal agreement between nomogram-predicted survival and actual observed survival. Additionally, significant distinctions in survival curves between different risk groups stratified by prognostic scores were also observed. The proposed nomogram was then deployed into a website server for convenient application. CONCLUSIONS: We developed and validated novel nomograms for individual prediction of survival for resected limited-stage SCLC patients. These models perform better than the previously widely used staging system and may offer clinicians instructions for strategy making and the design of clinical trials. SUPPLEMENTARY INFORMATION: The online version of this article (10.1245/s10434-020-09552-w) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-8349336
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-83493362021-08-20 Development and Validation of a Nomogram Prognostic Model for Resected Limited-Stage Small Cell Lung Cancer Patients Zeng, Qingpeng Li, Jiagen Tan, Fengwei Sun, Nan Mao, Yousheng Gao, Yushun Xue, Qi Gao, Shugeng Zhao, Jun He, Jie Ann Surg Oncol Thoracic Oncology BACKGROUND: In this study, we developed and validated nomograms for predicting the survival in surgically resected limited-stage small cell lung cancer (SCLC) patients. METHODS: The SCLC patients extracted from the Surveillance, Epidemiology, and End Results database between 2000 and 2014 were reviewed. Significant prognostic factors were identified and integrated to develop the nomogram using multivariable Cox regression. The model was then validated internally by bootstrap resampling, and externally using an independent SCLC cohort diagnosed between 2000 and 2015 at our institution. The prognostic performance was measured by the concordance index (C-index) and calibration curve. RESULTS: A total of 1006 resected limited-stage SCLC patients were included in the training cohort. Overall, 444 cases from our institution constituted the validation cohort. Seven prognostic factors were identified and entered into the nomogram construction. The C-indexes of this model in the training cohort were 0.723, 0.722, and 0.746 for predicting 1-, 3-, and 5-year overall survival (OS), respectively, and 0.816, 0.710, and 0.693, respectively, in the validation cohort. The calibration curve showed optimal agreement between nomogram-predicted survival and actual observed survival. Additionally, significant distinctions in survival curves between different risk groups stratified by prognostic scores were also observed. The proposed nomogram was then deployed into a website server for convenient application. CONCLUSIONS: We developed and validated novel nomograms for individual prediction of survival for resected limited-stage SCLC patients. These models perform better than the previously widely used staging system and may offer clinicians instructions for strategy making and the design of clinical trials. SUPPLEMENTARY INFORMATION: The online version of this article (10.1245/s10434-020-09552-w) contains supplementary material, which is available to authorized users. Springer International Publishing 2021-03-02 2021 /pmc/articles/PMC8349336/ /pubmed/33655361 http://dx.doi.org/10.1245/s10434-020-09552-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Thoracic Oncology
Zeng, Qingpeng
Li, Jiagen
Tan, Fengwei
Sun, Nan
Mao, Yousheng
Gao, Yushun
Xue, Qi
Gao, Shugeng
Zhao, Jun
He, Jie
Development and Validation of a Nomogram Prognostic Model for Resected Limited-Stage Small Cell Lung Cancer Patients
title Development and Validation of a Nomogram Prognostic Model for Resected Limited-Stage Small Cell Lung Cancer Patients
title_full Development and Validation of a Nomogram Prognostic Model for Resected Limited-Stage Small Cell Lung Cancer Patients
title_fullStr Development and Validation of a Nomogram Prognostic Model for Resected Limited-Stage Small Cell Lung Cancer Patients
title_full_unstemmed Development and Validation of a Nomogram Prognostic Model for Resected Limited-Stage Small Cell Lung Cancer Patients
title_short Development and Validation of a Nomogram Prognostic Model for Resected Limited-Stage Small Cell Lung Cancer Patients
title_sort development and validation of a nomogram prognostic model for resected limited-stage small cell lung cancer patients
topic Thoracic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349336/
https://www.ncbi.nlm.nih.gov/pubmed/33655361
http://dx.doi.org/10.1245/s10434-020-09552-w
work_keys_str_mv AT zengqingpeng developmentandvalidationofanomogramprognosticmodelforresectedlimitedstagesmallcelllungcancerpatients
AT lijiagen developmentandvalidationofanomogramprognosticmodelforresectedlimitedstagesmallcelllungcancerpatients
AT tanfengwei developmentandvalidationofanomogramprognosticmodelforresectedlimitedstagesmallcelllungcancerpatients
AT sunnan developmentandvalidationofanomogramprognosticmodelforresectedlimitedstagesmallcelllungcancerpatients
AT maoyousheng developmentandvalidationofanomogramprognosticmodelforresectedlimitedstagesmallcelllungcancerpatients
AT gaoyushun developmentandvalidationofanomogramprognosticmodelforresectedlimitedstagesmallcelllungcancerpatients
AT xueqi developmentandvalidationofanomogramprognosticmodelforresectedlimitedstagesmallcelllungcancerpatients
AT gaoshugeng developmentandvalidationofanomogramprognosticmodelforresectedlimitedstagesmallcelllungcancerpatients
AT zhaojun developmentandvalidationofanomogramprognosticmodelforresectedlimitedstagesmallcelllungcancerpatients
AT hejie developmentandvalidationofanomogramprognosticmodelforresectedlimitedstagesmallcelllungcancerpatients